Rosuvastatin (Crestor) and rhabdomyolysis

Open Access

20 July 2004

journal article
Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal

Vol. 171 (2) , 129
https://doi.org/10.1503/cmaj.1041051

Abstract

Reason for posting: Rosuvastatin (Crestor) is a relatively new cholesterol-lowering drug that has become one of the top-selling new pharmaceuticals since it was first marketed in Canada in February 2003. However, Health Canada recently alerted health care professionals of reports of rhabdomyolysis

Keywords

STATINS
RHABDOMYOLYSIS
CREATININE KINASE
KINASE LEVEL
ROSUVASTATIN
DRUG
SERIOUS
DENSITY LIPOPROTEIN

This publication has 3 references indexed in Scilit:

benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
The American Journal of Cardiology, 2003
Statin-Associated Myopathy
JAMA, 2003
Cerivastatin and Reports of Fatal Rhabdomyolysis
New England Journal of Medicine, 2002